Table 1

Demographic and clinical variables of the 140 patients with psoriatic arthritis included*

All patients with psoriatic arthritis N=140Females
N=71
Males
N=69
Age, years, mean (SD)52.4 (10.3)52.9 (10.3)51.9 (10.3)
Female, n (%)71 (50.7) NA NA
Postmenopausal, n (%)34 (24.3)34 (47.9) NA
Weight, kg, mean (SD)82.5 (14.7)79.2 (13.6)91.9 (13.0)
Height, cm, mean (SD)174.0 (8.8)168.2 (6.5)180.0 (6.6)
BMI, kg/m2, mean (SD)28.2 (4.2)28.0 (4.8)28.4 (3.6)
Disease duration, median (IQR)7.8 (9.3)7.6 (8.8)7.8 (10.4)
Smoking, n (%)
 Current23 (16.4)14 (19.7)9 (13.0)
 Previous72 (51.8)33 (46.5)39 (56.5)
Alcohol consumption (more than 3 units per day), n (%)1 (0.7)01 (1.4)
CRP, mg/L, median (IQR)2.0 (4.0)2.0 (3.0)3.0 (6.0)
ESR, mm/hour, median (IQR)13 (15)16 (16)10 (11)
Physical activity≥1 time per week, n (%)62 (44.3)33 (46.5)29 (42.0)
HLA B 27, n (%)34 (24.3)14 (19.7)20 (29.0)
DAS 28, mean (SD)3.16 (1.14)3.55 (1.08)2.74 (1.05)
BASDAI, mean (SD)3.35 (2.24)3.84 (2.34)2.84 (2.03)
MASES, mean (SD)2.97 (3.19)4.14 (3.39)1.77 (2.45)
PASI, mean (SD)2.56 (3.63)1.88 (2.94)3.24 (4.12)
Patient global assessment, mean (SD)36.12 (24.32)41.69 (25.15)30.39 (22.18)
Investigator global assessment, mean (SD)14.56 (12.11)14.69 (11.69)14.43 (11.00)
TJC 68, median (IQR)6 (14)8 (16)4 (9)
SJC 66, median (IQR)0 (1)0 (1)0 (1)
MHAQ, mean (SD)0.43 (0.40)0.50 (0.44)0.35 (0.33)
Current use of NSAIDs, n (%)45 (32.1)24 (33.8)21 (30.4)
Current use of synthetic DMARDs, n (%)80 (57.1)38 (53.5)42 (60.9)
Current use of biological DMARDs n (%)45 (32.1)18 (25.4)27 (39.1)
Current use of glucocorticoids, n (%)15 (10.7)10 (14.1)5 (7.2)
Ever use of glucocorticoids ≥5 mg ≥3 mg, n (%)37 (26.4)19 (26.8)18 (26.1)
Use of calcium or vitamin D supplements,n (%)17 (12.1)16 (22.5)1 (1.4)
Osteoporosis medication, n (%)3 (2.1)3 (4.2)0
Previous low energy fracture, n (%)9 (6.4)6 (8.5)3 (4.3)
  • *Unless stated, results are mean (±SD) for continuous variables or absolute values (percentages) for categorical variables.

  • Anti-TNFtherapy, anti-tumour necrosis factor therapy; BMI, body mass index; CRP, C-reactive protein;DAS-28, disease activity score for 28 joints with ESR; DMARD, disease modifyinganti rheumatic drug; ESR, erythrocyte sedimentation rate; HLA B 27, human leucocyteantigen B 27; MHAQ, Modified Health Assessment Questionnaire; NSAIDs, non-steroidalanti-inflammatory drugs; SJC 66, swollen joint count 66 joints; TJC 68, tenderjoint count 68 joints.